{"id":"selinexor-tablets","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Nausea"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Diarrhea"},{"rate":"20-30","effect":"Thrombocytopenia"},{"rate":"20-25","effect":"Anemia"},{"rate":"15-25","effect":"Vomiting"},{"rate":"15-20","effect":"Neutropenia"},{"rate":"10-15","effect":"Hyponatremia"}]},"_chembl":{"chemblId":"CHEMBL3545185","moleculeType":"Small molecule","molecularWeight":"443.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Selinexor selectively inhibits exportin 1 (XPO1/CRM1), a nuclear export protein responsible for transporting various cargo proteins including tumor suppressors out of the nucleus. By blocking this export, selinexor causes accumulation of tumor suppressors like p53, IκB, and PTEN in the nucleus, restoring their anti-cancer functions. This mechanism is particularly effective in hematologic malignancies and certain solid tumors where XPO1 is often overexpressed.","oneSentence":"Selinexor is a selective inhibitor of nuclear export (SINE) that blocks XPO1/CRM1, preventing the export of tumor suppressor proteins from the nucleus and leading to their accumulation and activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:50.846Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (in combination with dexamethasone)"},{"name":"Diffuse large B-cell lymphoma (DLBCL)"},{"name":"Acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT06158841","phase":"PHASE3","title":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-05-19","conditions":"Multiple Myeloma","enrollment":380},{"nctId":"NCT04925193","phase":"PHASE2","title":"Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-11-18","conditions":"Multiple Myeloma in Relapse","enrollment":18},{"nctId":"NCT05530421","phase":"PHASE2","title":"Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"University of Miami","startDate":"2023-03-26","conditions":"Relapsed and Refractory Multiple Myeloma","enrollment":33},{"nctId":"NCT06517511","phase":"PHASE2","title":"Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":42},{"nctId":"NCT05980806","phase":"PHASE2","title":"A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2024-04-22","conditions":"Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia","enrollment":58},{"nctId":"NCT05611931","phase":"PHASE3","title":"Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2023-04-18","conditions":"Endometrial Cancer","enrollment":276},{"nctId":"NCT04414475","phase":"PHASE2","title":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-07-01","conditions":"Multiple Myeloma, Refractory","enrollment":127},{"nctId":"NCT06239272","phase":"PHASE1, PHASE2","title":"NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-27","conditions":"Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma","enrollment":139},{"nctId":"NCT04216329","phase":"PHASE1","title":"Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-07","conditions":"Gliosarcoma, Newly Diagnosed, Glioblastoma","enrollment":11},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT05028348","phase":"PHASE3","title":"A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2022-04-19","conditions":"Multiple Myeloma","enrollment":117},{"nctId":"NCT04607772","phase":"PHASE1, PHASE2","title":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-11-18","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT04562389","phase":"PHASE3","title":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2021-03-11","conditions":"Myelofibrosis","enrollment":353},{"nctId":"NCT04562870","phase":"PHASE2","title":"A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2021-03-17","conditions":"Myelofibrosis","enrollment":112},{"nctId":"NCT02227251","phase":"PHASE2","title":"Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2014-11","conditions":"Diffuse Large B-cell Lymphoma","enrollment":244},{"nctId":"NCT07011056","phase":"PHASE3","title":"A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2025-07-18","conditions":"Recurrent and Refractory Diffuse Large B-cell Lymphoma","enrollment":390},{"nctId":"NCT05265975","phase":"PHASE1, PHASE2","title":"A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL","status":"TERMINATED","sponsor":"Antengene Corporation","startDate":"2022-04-07","conditions":"Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma","enrollment":54},{"nctId":"NCT04256707","phase":"PHASE1, PHASE2","title":"Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-01-14","conditions":"Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors","enrollment":126},{"nctId":"NCT04717700","phase":"PHASE2","title":"Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ida Bruun Kristensen","startDate":"2021-08-18","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT06813079","phase":"PHASE2","title":"Using Tumor Models to Determine Treatments","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-02-17","conditions":"Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial Tumor","enrollment":25},{"nctId":"NCT03555422","phase":"PHASE3","title":"Maintenance with Selinexor/Placebo After Combination Chemotherapy in Participants with Endometrial Cancer [SIENDO]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2018-01-05","conditions":"Endometrial Cancer","enrollment":263},{"nctId":"NCT04782687","phase":"PHASE2","title":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"US Oncology Research","startDate":"2021-09-10","conditions":"Multiple Myeloma, Myeloma Multiple, Kahler Disease","enrollment":73},{"nctId":"NCT04421378","phase":"PHASE1, PHASE2","title":"A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma","status":"TERMINATED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-06-08","conditions":"Glioblastoma Multiforme","enrollment":74},{"nctId":"NCT04768881","phase":"PHASE2","title":"Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma","status":"TERMINATED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2021-05-12","conditions":"Locally Advanced Unresectable or Metastatic Melanoma","enrollment":15},{"nctId":"NCT03110562","phase":"PHASE3","title":"Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2017-05-24","conditions":"Multiple Myeloma","enrollment":402},{"nctId":"NCT05478993","phase":"PHASE2","title":"Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-10-12","conditions":"Multiple Myeloma","enrollment":21},{"nctId":"NCT04595994","phase":"PHASE1","title":"Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma","status":"RECRUITING","sponsor":"Grupo Espanol de Investigacion en Sarcomas","startDate":"2020-09-02","conditions":"Sarcoma,Soft Tissue","enrollment":14},{"nctId":"NCT01896505","phase":"PHASE1","title":"A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2013-07-30","conditions":"Sarcoma","enrollment":54},{"nctId":"NCT04854434","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations","status":"TERMINATED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2021-06-29","conditions":"Metastatic Colorectal Cancer","enrollment":13},{"nctId":"NCT04843579","phase":"PHASE2","title":"Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2021-12-29","conditions":"Myeloma Multiple, Myeloma, Refractory Multiple Myeloma","enrollment":4},{"nctId":"NCT04534725","phase":"PHASE3","title":"COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;","status":"COMPLETED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2020-12-17","conditions":"Cancer, Covid19, Respiratory Viral Infection","enrollment":441},{"nctId":"NCT03193437","phase":"PHASE2","title":"Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2018-04-03","conditions":"Thymoma, Advanced Thymic Epithelial Tumor","enrollment":8},{"nctId":"NCT02628704","phase":"PHASE2","title":"Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-12","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02314247","phase":"PHASE2","title":"Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma","status":"TERMINATED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-02","conditions":"Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)","enrollment":16},{"nctId":"NCT01986348","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas","status":"TERMINATED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2014-03-03","conditions":"Glioblastoma, Glioma","enrollment":76},{"nctId":"NCT02025985","phase":"PHASE2","title":"Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2014-04-09","conditions":"Ovarian Carcinoma, Endometrial Carcinoma, Cervical Carcinoma","enrollment":116},{"nctId":"NCT02213133","phase":"PHASE2","title":"Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas","status":"TERMINATED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2014-09-22","conditions":"Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT02138786","phase":"PHASE2","title":"Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation","status":"TERMINATED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2014-11-14","conditions":"Richter's Transformation","enrollment":27},{"nctId":"NCT02088541","phase":"PHASE2","title":"Selinexor (KPT-330) in Older Patients With Relapsed AML","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2014-03","conditions":"Acute Myeloid Leukemia (AML)","enrollment":317},{"nctId":"NCT04355676","phase":"PHASE2","title":"Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-04-30","conditions":"Coronavirus Infection","enrollment":""},{"nctId":"NCT04349098","phase":"PHASE2","title":"Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-04-17","conditions":"Coronavirus Infection","enrollment":190},{"nctId":"NCT02186834","phase":"PHASE1, PHASE2","title":"Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2014-09-23","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT05093608","phase":"PHASE1","title":"SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-11-03","conditions":"Hepatocellular Carcinoma","enrollment":2},{"nctId":"NCT05201118","phase":"PHASE1","title":"A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma","status":"UNKNOWN","sponsor":"Chunrui Li","startDate":"2022-01-01","conditions":"Extramedullary Multiple Myeloma","enrollment":20},{"nctId":"NCT02269293","phase":"PHASE1","title":"Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-10-13","conditions":"Ovarian Cancer, Endometrial Cancer","enrollment":23},{"nctId":"NCT03880123","phase":"PHASE1","title":"Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma","status":"WITHDRAWN","sponsor":"Matthew Ingham","startDate":"2020-11","conditions":"Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Alveolar Soft Part Sarcoma","enrollment":""},{"nctId":"NCT03466827","phase":"PHASE2","title":"Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma","status":"UNKNOWN","sponsor":"Morten Mau-Soerensen","startDate":"2017-10-12","conditions":"Thymoma, Advanced Thymic Epithelial Tumour","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Selinexor Tablets","genericName":"Selinexor Tablets","companyName":"Chengdu Zenitar Biomedical Technology Co., Ltd","companyId":"chengdu-zenitar-biomedical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Selinexor is a selective inhibitor of nuclear export (SINE) that blocks XPO1/CRM1, preventing the export of tumor suppressor proteins from the nucleus and leading to their accumulation and activation. Used for Multiple myeloma (in combination with dexamethasone), Diffuse large B-cell lymphoma (DLBCL), Acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}